Evidence map›Paper›PMID 26811601›Full record

ReviewWorld journal of gastroenterology2016

Targeted therapies in gastric cancer and future perspectives.

Ozan Yazici, M Ali Nahit Sendur, Nuriye Ozdemir, Sercan Aksoy

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in World journal of gastroenterology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed, 1 pooled it
5.6field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 1 synthesis or guideline pooled it, 45 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Article
  18. Article
  19. Current Understanding of Circular RNAs in Gastric Cancer.Cancer management and research · 2019
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Ozan YaziciOzan Yazici, Nuriye Ozdemir, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara 06100, Turkey.
M Ali Nahit SendurOzan Yazici, Nuriye Ozdemir, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara 06100, Turkey.
Nuriye OzdemirOzan Yazici, Nuriye Ozdemir, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara 06100, Turkey.
Sercan AksoyOzan Yazici, Nuriye Ozdemir, Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara 06100, Turkey.
Ankara Numune Eğitim ve Araştırma Hastanesi · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Advanced gastric cancer (AGC) is associated with a high mortality rate and, despite multiple new chemotherapy options, the survival rates of patients with AGC remains poor. After the discovery of targeted therapies, research has focused on the new treatment options for AGC. In the last two decades, many targeted molecules were developed against AGC. Currently, two targeted therapy molecules have been approved for patients with AGC. In 2010, trastuzumab was the first molecule shown to improve survival in patients with HER2-positive AGC as part of a first-line combination regimen. In 2014, ramucirumab was the second targeted molecule to improve survival rates and was suggested as treatment for patients with AGC who had progressed after first-line platinum plus fluoropyrimidine with or without anthracycline chemotherapy. Ramucirumab was the first targeted therapy acting as a single agent in patients with advanced gastroesophageal cancers. Although these two molecules were introduced into clinical use, many other promising molecules have been tested in phase I-II trials. It is obvious that in the near future many different targeted therapies will be in use for treatment of AGC. In this review, the current status of targeted therapies in the treatment of AGC and gastroesophageal junction tumors, including HER (2-3) inhibitors, epidermal growth factor receptor inhibitors, tyrosine kinase inhibitors, antiangiogenic agents, c-MET inhibitors, mammalian target of rapamycin inhibitors, agents against other molecular pathways fibroblast growth factor, Claudins, insulin-like growth factor, heat shock proteins, and immunotherapy, will be discussed.

Indexed as

Angiogenesis InhibitorsAnimalsBiomarkers, TumorDiffusion of InnovationDrug DiscoveryForecastingHumansImmunotherapyMolecular Targeted TherapyProtein Kinase InhibitorsProtein-Tyrosine KinasesSignal TransductionStomach NeoplasmsAngiogenesis InhibitorsBiomarkers, TumorProtein Kinase InhibitorsProtein-Tyrosine KinasesAntibodiesGastric cancerSurvivalTargeted therapiesTyrosine kinase

Identifiers

PMID26811601
PMCPMC4716053
OpenAlexW2415006097

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.